Literature DB >> 7257030

ABH antigenicity of in situ carcinoma of the urinary bladder during intracavity treatment with doxorubicin hydrochloride.

G Jakse, F Hofstädter.   

Abstract

Ten patients with carcinoma in situ of the urinary bladder were treated topically with doxorubicin hydrochloride. Blood group antigens were evaluated by the specific red cell adherence tests. Carcinoma in situ was associated with the loss of antigenicity, the reappearance of which could be demonstrated in patients with tumour remission. This occurred in spite of a persistent nuclear atypia.

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 7257030     DOI： 10.1007/bf00254411

Source DB:  PubMed          Journal:  Urol Res        ISSN： 0300-5623


  13 in total

1.  Adriamycin-a review.

Authors:  S K Carter
Journal:  J Natl Cancer Inst       Date:  1975-12       Impact factor: 13.506

2.  DNA complexing antibiotics: daunomycin, adriamycin and their derivatives.

Authors:  A Marco; F Arcamone
Journal:  Arzneimittelforschung       Date:  1975-03

3.  Early immunologic diagnosis and prognosis of carcinoma. Philip Levine Award Address.

Authors:  I Davidsohn
Journal:  Am J Clin Pathol       Date:  1972-06       Impact factor: 2.493

4.  Classification of bladder tumours based on the cellular pattern. Preliminary report of a clinical-pathological study of 300 cases with a minimum follow-up of eight years.

Authors:  A Bergkvist; A Ljungqvist; G Moberger
Journal:  Acta Chir Scand       Date:  1965-10

5.  Intravesical doxorubicin hydrochloride in the management of carcinoma in situ of the bladder.

Authors:  G Jakse; F Hofstädter
Journal:  Eur Urol       Date:  1980       Impact factor: 20.096

6.  Tissue blood-group antigens and prognosis in low stage transitional cell carcinoma of the bladder.

Authors:  P H Lange; C Limas; E E Fraley
Journal:  J Urol       Date:  1978-01       Impact factor: 7.450

7.  The cell surface antigen A, B or O(H) as an indicator of malignant potential in stage A bladder carcinoma: preliminary report.

Authors:  S Bergman; N Javadpour
Journal:  J Urol       Date:  1978-01       Impact factor: 7.450

8.  Isoantigens A, B and H in urinary bladder carcinomas following radiotherapy.

Authors:  J Alroy; K Teramura; A W Miller; B U Pauli; J E Gottesman; M Flanagan; I Davisohn; R S Weinstein
Journal:  Cancer       Date:  1978-05       Impact factor: 6.860

9.  Further experiences with the specific red cell adherence test (SRCA) in bladder cancer. a histological and cytological study.

Authors:  G Jakse; F Hofstädter
Journal:  Eur Urol       Date:  1978       Impact factor: 20.096

10.  Blood group isoantigen deletion in carcinoma in situ of the urinary bladder.

Authors:  R S Weinstein; J Alroy; G M Farrow; A W Miller; I Davidsohn
Journal:  Cancer       Date:  1979-02       Impact factor: 6.860
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.